Drug Information

Drug General Information
Drug ID
D02TCZ
Former ID
DNC004778
Drug Name
2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527386]
Formula
C16H15N3OS
Canonical SMILES
C1CSCCN1C2=CC(=O)N3C=CC4=CC=CC=C4C3=N2
InChI
1S/C16H15N3OS/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2
InChIKey
LGFZVFQIQUWUBJ-UHFFFAOYSA-N
PubChem Compound ID
11289486
Target and Pathway
Target(s) DNA-dependent protein kinase catalytic subunit Target Info Inhibitor [527386]
KEGG Pathway Non-homologous end-joining
Cell cycle
NetPath Pathway IL1 Signaling Pathway
Pathway Interaction Database DNA-PK pathway in nonhomologous end joining
Coregulation of Androgen receptor activity
Class I PI3K signaling events mediated by Akt
BARD1 signaling events
Reactome Nonhomologous End-Joining (NHEJ)
WikiPathways DNA Damage Response
Non-homologous end joining
FAS pathway and Stress induction of HSP regulation
Cytosolic sensors of pathogen-associated DNA
Retinoblastoma (RB) in Cancer
Prostate Cancer
Double-Strand Break Repair
Cell Cycle
miRNA Regulation of DNA Damage Response
References
Ref 527386J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
Ref 527386J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.